{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:38:51Z","timestamp":1793039931009,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Oral Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>N<\/jats:italic>\n                    <jats:sup>1<\/jats:sup>\n                    -methyladenosine (m\n                    <jats:sup>1<\/jats:sup>\n                    A) RNA methylation is critical for regulating mRNA translation; however, its role in the development, progression, and immunotherapy response of head and neck squamous cell carcinoma (HNSCC) remains largely unknown. Using\n                    <jats:italic>Tgfbr1<\/jats:italic>\n                    and\n                    <jats:italic>Pten<\/jats:italic>\n                    conditional knockout (2cKO) mice, we found the neoplastic transformation of oral mucosa was accompanied by increased m\n                    <jats:sup>1<\/jats:sup>\n                    A modification levels. Analysis of m\n                    <jats:sup>1<\/jats:sup>\n                    A-associated genes identified TRMT61A as a key m\n                    <jats:sup>1<\/jats:sup>\n                    A writer linked to cancer progression and poor prognosis. Mechanistically, TRMT61A-mediated tRNA-m\n                    <jats:sup>1<\/jats:sup>\n                    A modification promotes MYC protein synthesis, upregulating programmed death-ligand 1 (PD-L1) expression. Moreover, m\n                    <jats:sup>1<\/jats:sup>\n                    A modification levels were also elevated in tumors treated with oncolytic herpes simplex virus (oHSV), contributing to reactive PD-L1 upregulation. Therapeutic m\n                    <jats:sup>1<\/jats:sup>\n                    A inhibition sustained oHSV-induced antitumor immunity and reduced tumor growth, representing a promising strategy to alleviate resistance. These findings indicate that m\n                    <jats:sup>1<\/jats:sup>\n                    A inhibition can prevent immune escape after oHSV therapy by reducing PD-L1 expression, providing a mutually reinforcing combination immunotherapy approach.\n                  <\/jats:p>","DOI":"10.1038\/s41368-024-00304-0","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T06:01:59Z","timestamp":1715320919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["m1A inhibition fuels oncolytic virus-elicited antitumor immunity via downregulating MYC\/PD-L1 signaling"],"prefix":"10.1038","volume":"16","author":[{"given":"Shujin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuantong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qichao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3812-3850","authenticated-orcid":false,"given":"Junjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5223-4659","authenticated-orcid":false,"given":"Bifeng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0932-8013","authenticated-orcid":false,"given":"Zhijun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"304_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"304_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson, D. E. et al. Head and neck squamous cell carcinoma. Nat. Rev. Dis. Primers 6, 92 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"304_CR3","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1634\/theoncologist.2009-0289","volume":"15","author":"D Pulte","year":"2010","unstructured":"Pulte, D. & Brenner, H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 15, 994\u20131001 (2010).","journal-title":"Oncologist"},{"key":"304_CR4","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.1038\/s41388-021-02022-x","volume":"40","author":"SL Gillen","year":"2021","unstructured":"Gillen, S. L., Waldron, J. A. & Bushell, M. Codon optimality in cancer. Oncogene 40, 6309\u20136320 (2021).","journal-title":"Oncogene"},{"key":"304_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nature16998","volume":"530","author":"D Dominissini","year":"2016","unstructured":"Dominissini, D. et al. The dynamic N(1)-methyladenosine methylome in eukaryotic messenger RNA. Nature 530, 441\u2013446 (2016).","journal-title":"Nature"},{"key":"304_CR6","doi-asserted-by":"publisher","first-page":"6578","DOI":"10.1016\/j.csbj.2022.11.045","volume":"20","author":"J Li","year":"2022","unstructured":"Li, J., Zhang, H. & Wang, H. N(1)-methyladenosine modification in cancer biology: Current status and future perspectives. Comput. Struct. Biotechnol. J. 20, 6578\u20136585 (2022).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"304_CR7","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/s41590-022-01301-3","volume":"23","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. tRNA-m(1)A modification promotes T cell expansion via efficient MYC protein synthesis. Nat. Immunol. 23, 1433\u20131444 (2022).","journal-title":"Nat. Immunol."},{"key":"304_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01500-4","volume":"21","author":"Y An","year":"2022","unstructured":"An, Y. & Duan, H. The role of m6A RNA methylation in cancer metabolism. Mol. Cancer 21, 14 (2022).","journal-title":"Mol. Cancer"},{"key":"304_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01558-0","volume":"21","author":"X Li","year":"2022","unstructured":"Li, X., Ma, S., Deng, Y., Yi, P. & Yu, J. Targeting the RNA m(6)A modification for cancer immunotherapy. Mol. Cancer 21, 76 (2022).","journal-title":"Mol. Cancer"},{"key":"304_CR10","doi-asserted-by":"publisher","first-page":"215937","DOI":"10.1016\/j.canlet.2022.215937","volume":"550","author":"SJ Li","year":"2022","unstructured":"Li, S. J. & Sun, Z. J. Fueling immune checkpoint blockade with oncolytic viruses: current paradigms and challenges ahead. Cancer Lett. 550, 215937 (2022).","journal-title":"Cancer Lett."},{"key":"304_CR11","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ccell.2020.12.022","volume":"39","author":"E Ramelyte","year":"2021","unstructured":"Ramelyte, E. et al. Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. Cancer Cell 39, 394\u2013406.e394 (2021).","journal-title":"Cancer Cell"},{"key":"304_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14754","volume":"8","author":"Z Liu","year":"2017","unstructured":"Liu, Z., Ravindranathan, R., Kalinski, P., Guo, Z. S. & Bartlett, D. L. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat. Commun. 8, 14754 (2017).","journal-title":"Nat. Commun."},{"key":"304_CR13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1172\/JCI98047","volume":"128","author":"D Zamarin","year":"2018","unstructured":"Zamarin, D. et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J. Clin. Invest. 128, 1413\u20131428 (2018).","journal-title":"J. Clin. Invest."},{"key":"304_CR14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/nrc2231","volume":"8","author":"N Meyer","year":"2008","unstructured":"Meyer, N. & Penn, L. Z. Reflecting on 25 years with MYC. Nat. Rev. Cancer 8, 976\u2013990 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"304_CR15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nrc3984","volume":"15","author":"TR Kress","year":"2015","unstructured":"Kress, T. R., Sab\u00f2, A. & Amati, B. MYC: connecting selective transcriptional control to global RNA production. Nat. Rev. Cancer 15, 593\u2013607 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"304_CR16","doi-asserted-by":"publisher","first-page":"a014357","DOI":"10.1101\/cshperspect.a014357","volume":"4","author":"M Conacci-Sorrell","year":"2014","unstructured":"Conacci-Sorrell, M., McFerrin, L. & Eisenman, R. N. An overview of MYC and its interactome. Cold Spring Harb. Perspect. Med. 4, a014357 (2014).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"304_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey, S. C. et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227\u2013231 (2016).","journal-title":"Science"},{"key":"304_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/318533a0","volume":"318","author":"JM Adams","year":"1985","unstructured":"Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533\u2013538 (1985).","journal-title":"Nature"},{"key":"304_CR19","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.1073\/pnas.79.24.7824","volume":"79","author":"R Dalla-Favera","year":"1982","unstructured":"Dalla-Favera, R. et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl Acad. Sci. USA 79, 7824\u20137827 (1982).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"304_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/1098-2264(200007)28:3<329::AID-GCC11>3.0.CO;2-F","volume":"28","author":"C Stock","year":"2000","unstructured":"Stock, C., Kager, L., Fink, F. M., Gadner, H. & Ambros, P. F. Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chromosomes Cancer 28, 329\u2013336 (2000).","journal-title":"Genes Chromosomes Cancer"},{"key":"304_CR21","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1158\/2159-8290.CD-19-0435","volume":"10","author":"NM Sodir","year":"2020","unstructured":"Sodir, N. M. et al. MYC instructs and maintains pancreatic adenocarcinoma phenotype. Cancer Discov. 10, 588\u2013607 (2020).","journal-title":"Cancer Discov."},{"key":"304_CR22","doi-asserted-by":"publisher","first-page":"dmm038083","DOI":"10.1242\/dmm.038083","volume":"12","author":"C Lourenco","year":"2019","unstructured":"Lourenco, C. et al. Modelling the MYC-driven normal-to-tumour switch in breast cancer. Dis. Model Mech. 12, dmm038083 (2019).","journal-title":"Dis. Model Mech."},{"key":"304_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","volume":"27","author":"D Mittal","year":"2014","unstructured":"Mittal, D., Gubin, M. M., Schreiber, R. D. & Smyth, M. J. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr. Opin. Immunol. 27, 16\u201325 (2014).","journal-title":"Curr. Opin. Immunol."},{"key":"304_CR24","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science 331, 1565\u20131570 (2011).","journal-title":"Science"},{"key":"304_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","volume":"19","author":"R Dhanasekaran","year":"2022","unstructured":"Dhanasekaran, R. et al. The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat. Rev. Clin. Oncol. 19, 23\u201336 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"304_CR26","doi-asserted-by":"publisher","first-page":"5304","DOI":"10.1158\/1078-0432.CCR-12-1371","volume":"18","author":"ZJ Sun","year":"2012","unstructured":"Sun, Z. J. et al. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin. Cancer Res. 18, 5304\u20135313 (2012).","journal-title":"Clin. Cancer Res."},{"key":"304_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature24456","volume":"551","author":"M Safra","year":"2017","unstructured":"Safra, M. et al. The m1A landscape on cytosolic and mitochondrial mRNA at single-base resolution. Nature 551, 251\u2013255 (2017).","journal-title":"Nature"},{"key":"304_CR28","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.molcel.2017.10.019","volume":"68","author":"X Li","year":"2017","unstructured":"Li, X. et al. Base-resolution mapping reveals distinct m(1)A methylome in nuclear- and mitochondrial-encoded transcripts. Mol. Cell 68, 993\u20131005.e1009 (2017).","journal-title":"Mol. Cell"},{"key":"304_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36691-x","volume":"14","author":"JH Choi","year":"2023","unstructured":"Choi, J. H. et al. Single-cell transcriptome profiling of the stepwise progression of head and neck cancer. Nat. Commun. 14, 1055 (2023).","journal-title":"Nat. Commun."},{"key":"304_CR30","doi-asserted-by":"publisher","first-page":"9897","DOI":"10.1128\/MCB.25.22.9897-9909.2005","volume":"25","author":"C Benassayag","year":"2005","unstructured":"Benassayag, C. et al. Human c-Myc isoforms differentially regulate cell growth and apoptosis in Drosophila melanogaster. Mol. Cell Biol. 25, 9897\u20139909 (2005).","journal-title":"Mol. Cell Biol."},{"key":"304_CR31","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"304_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrm.2017.77","volume":"19","author":"P Schimmel","year":"2018","unstructured":"Schimmel, P. The emerging complexity of the tRNA world: mammalian tRNAs beyond protein synthesis. Nat. Rev. Mol. Cell Biol. 19, 45\u201358 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"304_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41589-019-0420-5","volume":"16","author":"J Song","year":"2020","unstructured":"Song, J. et al. Differential roles of human PUS10 in miRNA processing and tRNA pseudouridylation. Nat. Chem. Biol. 16, 160\u2013169 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"304_CR34","first-page":"101369","volume":"32","author":"K Sri-Ngern-Ngam","year":"2022","unstructured":"Sri-Ngern-Ngam, K., Keawvilai, P., Pisitkun, T. & Palaga, T. Upregulation of programmed cell death 1 by interferon gamma and its biological functions in human monocytes. Biochem. Biophys. Rep. 32, 101369 (2022).","journal-title":"Biochem. Biophys. Rep."},{"key":"304_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26718-6","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. N(1)-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism. Nat. Commun. 12, 6314 (2021).","journal-title":"Nat. Commun."},{"key":"304_CR36","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/JLB.5MR1120-778R","volume":"110","author":"S Wen","year":"2021","unstructured":"Wen, S. et al. TCF-1 maintains CD8(+) T cell stemness in tumor microenvironment. J. Leukoc. Biol. 110, 585\u2013590 (2021).","journal-title":"J. Leukoc. Biol."},{"key":"304_CR37","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.3390\/ijms24054326","volume":"24","author":"M Mammadli","year":"2023","unstructured":"Mammadli, M., Suo, L., Sen, J. M. & Karimi, M. TCF-1 is required for CD4 T cell persistence functions during alloImmunity. Int. J. Mol. Sci. 24, 4326 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"304_CR38","first-page":"549","volume":"78","author":"YY Silaeva","year":"2013","unstructured":"Silaeva, Y. Y. et al. Decrease in pool of T lymphocytes with surface phenotypes of effector and central memory cells under influence of TCR transgenic \u03b2-chain expression. Biochemistry 78, 549\u2013559 (2013).","journal-title":"Biochemistry"},{"key":"304_CR39","doi-asserted-by":"publisher","first-page":"583084","DOI":"10.3389\/fimmu.2020.583084","volume":"11","author":"Y Pan","year":"2020","unstructured":"Pan, Y., Yu, Y., Wang, X. & Zhang, T. Tumor-associated macrophages in tumor immunity. Front. Immunol. 11, 583084 (2020).","journal-title":"Front. Immunol."},{"key":"304_CR40","doi-asserted-by":"publisher","first-page":"866","DOI":"10.12998\/wjcc.v2.i12.866","volume":"2","author":"G Yardimci","year":"2014","unstructured":"Yardimci, G., Kutlubay, Z., Engin, B. & Tuzun, Y. Precancerous lesions of oral mucosa. World J. Clin. Cases 2, 866\u2013872 (2014).","journal-title":"World J. Clin. Cases"},{"key":"304_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29790-8","volume":"13","author":"Z Su","year":"2022","unstructured":"Su, Z. et al. TRMT6\/61A-dependent base methylation of tRNA-derived fragments regulates gene-silencing activity and the unfolded protein response in bladder cancer. Nat. Commun. 13, 2165 (2022).","journal-title":"Nat. Commun."},{"key":"304_CR42","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1021\/acs.chemrestox.9b00372","volume":"33","author":"BF Yuan","year":"2020","unstructured":"Yuan, B. F. Assessment of DNA epigenetic modifications. Chem. Res. Toxicol. 33, 695\u2013708 (2020).","journal-title":"Chem. Res. Toxicol."},{"key":"304_CR43","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ccr.2014.06.014","volume":"26","author":"Y Li","year":"2014","unstructured":"Li, Y., Choi, P. S., Casey, S. C., Dill, D. L. & Felsher, D. W. MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell 26, 262\u2013272 (2014).","journal-title":"Cancer Cell"},{"key":"304_CR44","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.tcb.2014.10.006","volume":"25","author":"E Wolf","year":"2015","unstructured":"Wolf, E., Lin, C. Y., Eilers, M. & Levens, D. L. Taming of the beast: shaping Myc-dependent amplification. Trends Cell Biol. 25, 241\u2013248 (2015).","journal-title":"Trends Cell Biol."},{"key":"304_CR45","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567\u2013578 (2006).","journal-title":"N. Engl. J. Med."},{"key":"304_CR46","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 1915\u20131928 (2019).","journal-title":"Lancet"},{"key":"304_CR47","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856\u20131867 (2016).","journal-title":"N. Engl. J. Med."},{"key":"304_CR48","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","volume":"17","author":"TY Seiwert","year":"2016","unstructured":"Seiwert, T. Y. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 17, 956\u2013965 (2016).","journal-title":"Lancet Oncol."},{"key":"304_CR49","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","volume":"11","author":"YT Liu","year":"2021","unstructured":"Liu, Y. T. & Sun, Z. J. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 11, 5365\u20135386 (2021).","journal-title":"Theranostics"},{"key":"304_CR50","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3389\/fimmu.2019.02022","volume":"10","author":"Y Wu","year":"2019","unstructured":"Wu, Y., Chen, W., Xu, Z. P. & Gu, W. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front. Immunol. 10, 2022 (2019).","journal-title":"Front. Immunol."},{"key":"304_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41421-023-00521-7","volume":"9","author":"J Yu","year":"2023","unstructured":"Yu, J. et al. Nuclear PD-L1 promotes EGR1-mediated angiogenesis and accelerates tumorigenesis. Cell Discov. 9, 33 (2023).","journal-title":"Cell Discov."},{"key":"304_CR52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41392-021-00500-y","volume":"6","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. Alternative approaches to target Myc for cancer treatment. Signal Transduct. Target Ther. 6, 117 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"304_CR53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/biom7010020","volume":"7","author":"S Oerum","year":"2017","unstructured":"Oerum, S., D\u00e9gut, C., Barraud, P. & Tisn\u00e9, C. m1A post-transcriptional modification in tRNAs. Biomolecules 7, 20 (2017).","journal-title":"Biomolecules"},{"key":"304_CR54","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti, R. et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286\u2013299 (2009).","journal-title":"Cell"},{"key":"304_CR55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41368-023-00229-0","volume":"15","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. LIMP-2 enhances cancer stem-like cell properties by promoting autophagy-induced GSK3\u03b2 degradation in head and neck squamous cell carcinoma. Int. J. Oral Sci. 15, 24 (2023).","journal-title":"Int. J. Oral Sci."},{"key":"304_CR56","doi-asserted-by":"publisher","first-page":"216105","DOI":"10.1016\/j.canlet.2023.216105","volume":"558","author":"B Zhang","year":"2023","unstructured":"Zhang, B. et al. Single-cell chemokine receptor profiles delineate the immune contexture of tertiary lymphoid structures in head and neck squamous cell carcinoma. Cancer Lett. 558, 216105 (2023).","journal-title":"Cancer Lett"},{"key":"304_CR57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41368-023-00242-3","volume":"15","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Knockdown of PGC1\u03b1 suppresses dysplastic oral keratinocytes proliferation through reprogramming energy metabolism. Int. J. Oral Sci. 15, 37 (2023).","journal-title":"Int. J. Oral Sci."},{"key":"304_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13471-0","volume":"10","author":"Z Wang","year":"2019","unstructured":"Wang, Z. et al. Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. Nat. Commun. 10, 5546 (2019).","journal-title":"Nat. Commun."}],"container-title":["International Journal of Oral Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41368-024-00304-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41368-024-00304-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41368-024-00304-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T06:02:06Z","timestamp":1715320926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41368-024-00304-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["304"],"URL":"https:\/\/doi.org\/10.1038\/s41368-024-00304-0","relation":{},"ISSN":["2049-3169"],"issn-type":[{"value":"2049-3169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"assertion":[{"value":"7 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}